消息面上，11月21日，恒生指数系列季度检讨结果出炉，所有变动将于2025年12月8日起生效。其中， 信达生物将被纳入恒生指数成份股，成份股数目将由88只增加至89只。 信达生物(01801)一度涨近5%，截至发稿，涨3.9%，报90.65港元，成交额1.77亿港元。 值得一提的是，11月20日，信达生物宣布，玛仕度肽注射液(胰高血糖素[GCG]/胰高血糖素样肽-1[GLP- 1]双受体激动剂，研发代号：IBI362)在中国中重度肥胖人群中开展的III期临床研究(GLORY-2)达成主要 终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg用于成人体重控制的新药上 市申请。 ...

智通财经APP获悉，信达生物(01801)一度涨近5%，截至发稿，涨3.9%，报90.65港元，成交额1.77亿港 元。 消息面上，11月21日，恒生指数系列季度检讨结果出炉，所有变动将于2025年12月8日起生效。其中， 信达生物将被纳入恒生指数成份股，成份股数目将由 88 只增加至 89 只。 值得一提的是，11月20日，信达生物宣布，玛仕度肽注射液（胰高血糖素[GCG] /胰高血糖素样 肽-1[GLP-1] 双受体激动剂，研发代号：IBI362）在中国中重度肥胖人群中开展的III期临床研究 （GLORY-2）达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg用于 成人体重控制的新药上市申请。 ...

Group 1 - The core point of the article is the inclusion of Innovent Biologics in the Hang Seng ESG Enhanced Index as part of the quarterly index review by Hang Seng Indexes Company [1] Group 2 - The announcement was made on November 21, indicating a significant update in the ESG index landscape [1] - The review also included the Hang Seng ESG Enhanced Select Index and the Hang Seng China Enterprises ESG Enhanced Index, highlighting a broader focus on ESG criteria [1]

Group 1 - Hang Seng Index will include Innovent Biologics (01801), increasing the number of constituent stocks from 88 to 89 [1][4] - Hang Seng China Enterprises Index will include China Hongqiao (01378), Innovent Biologics, and Yum China (09987), while New Energy (02688) and New Oriental-S (09901) will be removed, maintaining a total of 50 constituent stocks [3][5] - Hang Seng Technology Index will include Leapmotor (09863), while ASMPT (00522) will be removed, keeping the number of constituent stocks at 30 [7][9] Group 2 - Hang Seng Composite Index will include FWD Group (01828), Hesai Technology-W (02525), Aux Group (02580), Geekplus Technology-W (02590), Yino Pharma (02591), and Chery Automobile (09973), increasing the number of constituent stocks from 503 to 509 [10][11][12]

智通财经APP获悉，11月21日，恒生指数公司宣布截至2025年9月30日之恒生指数系列季度检讨结果， 所有变动将于2025年12月5日(星期五)收市后实施并于2025年12月8日(星期一)起生效。其中，信达生物 (01801)将被纳入恒生指数成份股，成份股数目将由88只增加至89只。 1.恒生指数 信达生物(01801)将被纳入恒生指数成份股，成份股数目将由 88 只增加至 89 只。 | 代号 | 公司 | 恒指分类指数 | | --- | --- | --- | | 1801 | 信达生物制药 | 恒生工商业分类指数 | 2.恒生中国企业指数 中国宏桥(01378)、信达生物、百胜中国(09987)将被纳入恒生中国企业指数成份股，新奥能源(02688)、 新东方-S(09901)等将被剔除。成份股数目维持50只。 3.恒生科技指数 零跑汽车(09863)将被纳入恒生科技指数成份股，ASMPT(00522)将被剔除，成份股数目维持30只。 | 代름 | 公司 | | --- | --- | | 1378 | 中国宏桥集团有限公司 | | 1801 | 信达生物制药 | | 9987 | 百胜中国控股有限公 ...

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

智通财经APP获悉，三款创新药发布公告取得有效进展，或引领恒生生物科技指数+恒生创新药指数企 稳。 1、11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临床研究 (GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg用于成 人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 2、2025年11月20日，复宏汉霖(02696)宣布，创新型PD-1抑制剂H药 汉斯状®(斯鲁利单抗，欧洲商品 名：Hetronifly®)被国家药品监督管理局(NMPA)药品审评中心(CDE)正式纳入突破性治疗品种名单，联 合化疗用于新辅助/辅助治疗胃癌，成为首个获CDE突破性疗法认定的胃癌围手术期治疗药物。 此次获得突破性疗法认定，标志着H药在胃癌围手术期治疗中的潜力与临床价值获得权威认可，有望 ...

Core Insights - The article highlights the successful completion of the GLORY-2 Phase III clinical trial for the world's first GCG/GLP-1 dual receptor agonist, Masitide, developed by Innovent Biologics, targeting severe obesity in China [1][2][3] - The trial demonstrated significant weight loss and improvements in various metabolic parameters among participants with a BMI ≥ 30 kg/m², indicating a potential new treatment option for a population lacking effective pharmacological interventions [1][2] Group 1: Clinical Trial Results - The GLORY-2 study included 462 participants with simple obesity and obesity combined with diabetes, randomized in a 2:1 ratio to receive either Masitide 9mg or a placebo for 60 weeks [2] - Results showed that the Masitide 9mg group achieved significant weight loss compared to the placebo group, along with reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels [2] Group 2: Market Potential and Regulatory Plans - Innovent Biologics plans to submit a marketing application for Masitide 9mg to the National Medical Products Administration (NMPA) for adult weight control [3] - The development of Masitide 9mg specifically addresses the weight management needs of patients with a BMI greater than 30 kg/m², particularly those above 32.5 kg/m², who previously relied on surgical interventions for effective weight management [3]

消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港元。 ...

智通财经APP获悉，信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港 元。 消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 ...